- Home
- ZDAI vs CMMB Comparison
ZDAI vs CMMB Comparison
Compare ZDAI & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZDAI | CMMB |
|---|---|---|
| Founded | 2022 | 2004 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6M | 13.8M |
| IPO Year | 2023 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ZDAI | CMMB |
|---|---|---|
| Price | $1.64 | $2.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 47.3K | ★ 88.6K |
| Earning Date | 05-15-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $64.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $1.35 |
| 52 Week High | $11.48 | $3.55 |
Technical Indicators
Market Signals| Indicator | ZDAI | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 43.62 | 78.71 |
| Support Level | $1.62 | $1.45 |
| Resistance Level | $2.04 | $2.82 |
| Average True Range (ATR) | 0.17 | 0.15 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 13.00 | 90.48 |
Price Performance
Historical ComparisonAbout ZDAI Primega Group Holdings Limited Ordinary Shares
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.